Who can use BRAFTOVI(Encorafenib)?

Melanoma

Binimetinib combined with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic BRAFV600E/K mutation-positive melanoma.

Colorectal Cancer (CRC)

Encorafenib in combination with cetuximab and the mFOLFOX6 regimen (fluorouracil, leucovorin, oxaliplatin) is used as first-line therapy (accelerated approval) for adult patients with BRAFV600E mutation-positive metastatic colorectal cancer.

Encorafenib combined with cetuximab is indicated for adult patients with BRAFV600E mutation-positive metastatic colorectal cancer who have failed prior therapy.

Non-Small Cell Lung Cancer (NSCLC)

Encorafenib combined with binimetinib is used for the treatment of adult patients with BRAFV600E mutation-positive metastatic non-small cell lung cancer.

Related Columns

Encorafenib(BRAFTOVI)

For the treatment of melanoma, colorectal cancer (CRC), and non-small cell lung...

WeChat Scan
Free Inquiry

Indications of Encorafenib (Braftovi)

Encorafenib (Braftovi) is an oral kinase inhibitor that first received approval for marketing from the U.S. Food and Drug Administration (FDA) in 2018. Specifically designed to treat malignant tumors ...

Efficacy,side effects and precautions of Encorafenib

Encorafenib, also known as Encorafenib, is a targeted drug used to treat specific types of lesions. It is mainly used for the treatment of BRAF-V600E or V600K mutation-positive unresectable or metasta...

Therapeutic Uses of Encorafenib.

Encorafenib is a highly effective targeted drug targeting specific gene mutations, mainly for the treatment of unresectable or metastatic melanoma positive for BRAF-V600E or V600K mutations, and metas...

What conditions can be treated with Encorafenib?

Encorafenib, also known as Encorafenib, is a targeted drug used to treat specific types of lesions. It prevents the growth and spread of diseased cells by inhibiting BRAF-V600E or V600K mutations. Enc...